Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


Stem Cell Media Interview With Dr. Adrian Harel: Fighting to End ALS, Once and for All

NEW YORK, NY and PETACH TIKVAH, ISRAEL -- (Marketwire) -- 12/04/12 -- Sai Rosen of www.InvestorStemCell.com (Stem Cell Media, LLC) recently sat down with Dr. Adrian Harel, Chief Executive Officer for Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI). Brainstorm Cell Therapeutics Inc. is a biotechnology company developing autologous stem cell therapies for highly debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD) and Spinal Cord Injury. These diseases have limited treatment options and as such represent unmet medical needs.

Dr. Harel has over 30 years' experience in international business development, marketing, clinical development, fund raising and building strategic partnerships. In January 2011, he came to Brainstorm and leveraged all his experience to transform the company from a struggling pre-clinical biotech to the world's leader in clinical stage neurodegenerative treatment for ALS. The company is nearing submission of an ALS Phase II, to be conducted at the renowned Massachusetts General Hospital (MGH).

During his interview, Dr. Harel shared the following information:

Why are you interested in neurodegenerative disorders?

Dr. Harel: "I became fascinated in this area of research while working at Proneuron Biotechnologies. We had created the 'world center' for paralysis. I had the pleasure to work with Christopher Reeve and other clinical leaders. We pioneered these early stage cellular treatments and I was pleased to have played a significant role in regulatory and managing endeavors across multiple channels both internal and external."

What brought you to Brainstorm?

Dr. Harel: "I have spent my whole life helping others, working with teams that are inspired to find solutions to difficult biological problems with the end goal to ease the burden of suffering. ALS is in my opinion the worst of the worst when considering unmet neurodegenerative diseases. I believe our data from the ALS Phase I is showing measurable improvements in key areas of those afflicted and may be proven to be a treatment for ALS."

What is the credit market like?

Dr. Harel: "It has been difficult to engage in terms that are not burdensome to goals. It is a fine line to ensure solvency, manage dilution and move our clinical trials forward as expeditiously as possible. I was able to arrange favorable terms early this summer and closed in July on a $5.7 million Public Offering. We have been successful with securing non-dilutive grants. Since coming to Brainstorm in January, I have raised over $10 million."

What is next for Brainstorm?

Dr. Harel: "We concluded our ALS Phase I trial in Israel recently. We are nearing filing with the FDA a Phase II ALS trial to be conducted at MGH in Boston. We are progressing and we are pleased with the initial safety and efficacy we are seeing. I anticipate beginning the trial at MGH in early 2013."

What would you say to those living with ALS?

Dr. Harel: "I wake up every day with the charge to end ALS. I will not rest and I will not give up until I find a viable cellular solution for treatment and a disease reversal leading to a cure. I am excited about the data we have. Very few companies are working towards a treatment for ALS and that makes me work even harder knowing that so many are depending on us."

Do you see a time when ALS will be no more?

Dr. Harel: "Simply put, yes! We are working with the best researchers and clinicians in Israel and soon to be working with the best in the USA. I am not giving up."

Sai Rose concluded, "In my years of interviewing CEOs of companies, I have never met a more passionate CEO than Dr. Harel. He has the entire skill set package that is needed to succeed and grow a clinical stage company."

About Stem Cell Media, LLC.

Stem Cell Media, LLC. (SCM) is the world's 1st and only media company dedicated to the regenerative medicine sector. www.Investorstemcell.com is an online social media forum dedicated to investors interested in public companies using stem cells.

Contact:

Stem Cell Media, LLC.
508-627-7250

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Web 2.0 Latest News
What winning sales organizations do to separate themselves from the competition by creating market advantage through improved user experiences and better information services. The next BriefingsDirect thought-leader interview focuses on what winning sales organizations do to separate...
Need a crash course on what DevOps is, how to foster a collaborative environment, and how to measure the effectiveness? We created a DevOps course, which presents you with a series of interactive questions to test your knowledge. Having just viewed the course myself, I have to say i...
DevOps has quickly become the buzzword du jour for the software industry and promotes something that many developers and IT Administrators don’t enjoy: collaboration. According to Wikipedia, “DevOps acknowledges the interdependence of software development, quality assurance, and IT ope...
You’ve got to test your website with mobile users even if you don’t have a mobile app or dedicated mobile presence. We see this in our discussions here at Neotys all the time: we’ll be asking someone about their mobile strategy and they’ll say, “Our mobile team does that.” Even if you ...
One reason a lot of entrepreneurs flock to cloud-based services for their business is the cost. Native applications require licenses that are either too expensive or require elaborate set-up across all devices. In a recent article on the Entrepreneur, Bask Iyer, the CIO and Senior Vic...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE